Transgene – R&D Day
Modulating the tumor micro-environment

Update and perspective on
Transgene’s strategy
Philippe Archinard, PhD
Chairman and CEO, Transgene
View presentation
Immunotherapy combinations,
a game-changer in lung cancer therapy
Karen Kelly, MD
Associate Director for Clinical Research, UC Davis Comprehensive Cancer Center
View presentation
Novel immuno-oncology
approaches in liver cancer
Olivier Rosmorduc, MD
Head of hepato-gastroenterology, La Pitié-Salpétrière
View presentation
Transgene’s clinical development
strategy in the evolving immuno-oncology landscape
Maud Brandely, MD, PhD
Chief Medical Officer, Transgene
View presentation
Immune modulators and immuno-oncology
Where do we stand
and where should we go next?
Christian Ottensmeier, MD, PhD
Director, NIHR CRUK Experimental Cancer Medicine Centre
View presentation
Engineering viruses to design
the next generation of immunotherapy
Eric Quéméneur, PhD
Chief Scientific Officer, Transgene
View presentation
Effective translational research,
the benefits of academic
Eliane Piaggio, PhD
Head of the translational research in immunotherapy team, INSERM/Institut Curie
View presentation

Closing remarks Philippe Archinard, PhD, Chairman and CEO, Transgene
Maud Brandely, MD, PhD, Chief Medical Officer, Transgene
Eric Quéméneur, PhD, Chief Scientific Officer, Transgene
View presentation

  Transgene SA - 400 Boulevard Gontier d'Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France
Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11
© 2016 Transgene - All rights reserved
Terms of Use